Actually there will be no more interim review since enrollment was fast enough that they will get full results before the 75% interim review would have happened. Therefore, there’s no point. You seem to be in love with HGEN, but I check out bunch of stocks and have not seen anything as convincing. If you think HGEN is so much better than CYDY, you’re living in your own world. CYDY’s trial did not have to increase enrollment to have enough power to the study. That means HGEN is probably effective, but just not as much as CYDY’s drug. I will probably buy some HGEN shares if it drops in price because I believe there is need for multiple therapeutics and I think HGEN might be the alternative. But I also have to think that there is a possibility that HGEN might not be able to finish enrollment either if CYDY gets full approval. So I will wait to see what price it is at to weigh the risk. I also didn’t see lenzilumab with a CMS code, so obviously the result hasn’t been that good either. I believe in the interim results of 32% better than SoC, which is worth something. I am certain Leronlimab will be much better than that, and the market agrees. HGEN has much more exposure than CYDY btw, it’s a NASDAQ stock and part of a government trial. Personally, it lost luster for me when I saw the interim results.
Market Data 
Markets 
AI
